Clinical Impact of New Rheumatoid Arthritis Data from APLAR 2019, JCR 2019, and EULAR 2019*

Withdrawal of csDMARDs had no significant effect on ongoing clinical response compared with continuation of csDMARDs or use of sarilumab monotherapy.

IV formulation of prednisolone was more effective than standard IM methylprednisolone for treating RA flares.

Add-on therapy with JAK1 inhibitor filgotinib demonstrated improved responses compared with placebo in patients with RA who had inadequate response to methotrexate.

Addition of JAK1 inhibitor to methotrexate improved ACR20 responses compared with methotrexate alone in methotrexate-naive patients with RA.

Tofacitinib monotherapy after methotrexate withdrawal does not worsen disease activity in RA patients who previously achieved low disease activity with tofacitinib plus methotrexate.

Prednisone tapering may be feasible in some RA patients with low disease activity or remission on tocilizumab, although continuous treatment provided superior disease control.

SC formulation of CT-P13 demonstrated noninferior efficacy compared to IV formulation for change in DAS28-CRP from baseline to Week 22 in patients with rheumatoid arthritis.

Baricitinib demonstrates acceptable safety in RA patients exposed for up to 7 yrs

Analysis of pooled data from 5 phase III RCTs in RA patients suggests similarities and differences in safety profile of upadacitinib vs methotrexate or adalimumab.

Monotherapy with the investigational JAK1 inhibitor upadacitinib showed sustained clinical improvements and safety outcomes through 48 weeks in patients with RA with inadequate response to methotrexate.